Familial hypercholesterolemia (FH) is an autosomal codominant lipoprotein disorder characterized by elevated low-density lipoprotein cholesterol (LDL-C) and high risk of premature atherosclerotic cardiovascular disease.
clinics. The most commonly used diagnostic algorithms for FH are the Simon Broome Register (SBR) and the Dutch Lipid Clinic Network (DLCN) criteria, which incorporate LDL-C, clinical signs, and family history of premature atherosclerotic cardiovascular disease (ASCVD) and an elevated LDL-C > 95th percentile in a first-degree relative to generate a score that leads to classification of either "definite," "probable," or "possible" FH (Supplemental Tables S1 and S2 ). Detection of a pathogenic DNA mutation in an FH-related gene in a proband leads to a diagnosis of "definite FH." There are important limitations to the currently used algorithms: the clinical manifestations are infrequent; the baseline LDL-C (untreated) level is often unavailable because of the use of lipid-lowering therapies; and, family history is sometimes unavailable or unreliable. DNA testing is not readily available and not always concordant with the FH phenotype. Despite the complexities, diagnosis is important because untreated FH leads to premature ASCVD, whereas early identification and treatment can normalize risk. 1 Heterozygous FH has a prevalence of approximately 1:250 2 and might be higher in populations with founder effects, as in the province of Qu ebec. The homozygous form is rare and constitutes an orphan disease. Age of onset of ASCVD can vary considerably in FH subjects and in addition to sex, depends on the severity of the mutation and other risk factors. The increase in ASCVD risk remains across a broad range of elevated LDL-C levels and is at least sixfold higher even in the absence of documented FH-causing mutations. Currently used criteria are difficult to use. We therefore propose to redefine FH on the basis of simplified criteria as a genetic condition characterized by marked elevations in LDL-C and risk of early onset ASCVD (Supplemental Table S3 ). We provide Canadaspecific LDL-C cut points and a validated calculation for an imputed LDL-C, on the basis of the type and intensity of lipid-lowering therapy. 3 
Methods
See the Material and Methods section of the Supplementary Material.
Results

Screening criteria for FH
The 95th percentile cut points for LDL-C are shown in Supplemental Figure S2 ; frequency distribution according to age and sex is shown in Supplemental Table S4 . Overall, the 95th percentile for the population was 5.0 mmol/L in men and in women. The 95th percentile value for LDL-C in men younger than 18, 18-39, and older than 40 years were 3.67, 4.79, and 5.08 mmol/L, respectively. In women, these were 3.70, 4.27, and 5.18 mmol/L, respectively. We therefore selected the LDL-C cut points of ! 4.0 mmol/L for men and women younger than 18 years, ! 4.5 mmol/L for ages 18-39 years, and ! 5.0 mmol/L for subjects 40 years of age and older (Supplemental Table S3 ). These LDL-C levels constitute an obligatory major criterion for the diagnosis of FH and should be confirmed on repeat testing.
Along with the DLCN criteria, an LDL-C ! 8.5 mmol/L has > 99% specificity for a diagnosis of FH in genetically confirmed patients.
Definitions for FH rely on complex algorithms that are on the basis of levels of total or LDL-C, clinical features, family history, and DNA analysis that are often difficult to obtain. We propose a novel simplified definition for FH. Definite FH includes: (1) elevated LDL-C (! 8.50 mmol/L); or (2) LDL-C ! 5.0 mmol/L (for age 40 years or older; ! 4.0 mmol/L if age younger than 18 years; and ! 4.5 mmol/L if age is between 18 and 39 years) when associated with at least 1 of: (1) tendon xanthomas; or (2) causal DNA mutation in the LDLR, APOB, or PCSK9 genes in the proband or first-degree relative. Probable FH is defined as subjects with an elevated LDL-C (! 5.0 mmol/L) and the presence of premature atherosclerotic cardiovascular disease in the patient or a first-degree relative or an elevated LDL-C in a first-degree relative. LDL-C cut points were determined from a large database comprising > 3.3 million subjects. To compare the proposed definition with currently used algorithms (ie, the Simon Broome Register and Dutch Lipid Clinic Network), we performed concordance analyses in 5987 individuals from Canada. The new FH definition showed very good agreement compared with the Simon Broome Register and Dutch Lipid Clinic Network criteria (k ¼ 0.969 and 0.966, respectively). In conclusion, the proposed FH definition has diagnostic performance comparable to existing criteria, but adapted to the Canadian population, and will facilitate the diagnosis of FH patients. maladie cardiovasculaire ath eroscl ereuse pr ematur ee. Les d efinitions de l'HF reposent sur des algorithmes complexes bas es sur les concentrations de cholest erol total ou de cholest erol LDL, les caract eristiques cliniques, les ant ec edents familiaux et les analyses de l'ADN souvent difficiles à obtenir. Nous proposons une nouvelle d efinition simplifi ee de l'HF. Pour un diagnostic d efinitif d'HF, il faut : 1) un taux elev e de cholest erol LDL (! 8,50 mmol/l) ou 2) un taux de cholest erol LDL ! 5,0 mmol/l (pour les 40 ans et plus); ! 4,0 mmol/l (pour les moins de 18 ans); ! 4,5 mmol/l (de 18 à 39 ans) lorsque associ e à au moins l'une des caract eristiques suivantes : 1) un xanthome tendineux; ou 2) une mutation causale de l'ADN observ ee dans les gènes LDLR, APOB ou PCSK9 chez le propositus ou les parents de premier degr e. L'HF probable concerne les sujets qui ont un taux elev e de cholest erol LDL (! 5,0 mmol/l) et qui montrent la pr esence d'une maladie cardiovasculaire ath eroscl ereuse pr ematur ee chez le patient ou les parents de premier degr e, ou un taux elev e de cholest erol LDL chez les parents de premier degr e. Les 
FH criteria: major
Xanthomas, corneal arcus and xanthelasmas. The prevalence of cutaneous manifestations of FH has decreased markedly in the statin era. In 268 new FH patients diagnosed according to the DLCN or SBR criteria examined in the Qu ebec City Lipid clinic, CHU de Qu ebec-Universit e Laval, and the Chicoutimi Hospital Lipid Clinic after 2012, only 20% had tendon xanthomas and none had premature corneal arcus or xanthelasmas (Supplemental Fig. S1 ). However, tendon xanthomas, which are highly specific of FH in subjects with genetic high LDL-C, are included in the DLCN and SBR criteria as a major clinical diagnostic criterion. Corneal arcus after age 45 and xanthelasma are not specific for FH and were not considered in the proposed definition of FH.
DNA mutation. The presence of a known pathogenic mutation in the LDLR, APOB, or PCSK9 genes is a major criterion for FH. The availability of next-generation sequencing now allows the rapid and unbiased molecular diagnosis of FH using exome sequencing of the LDLR, APOB, or PCSK9 and capture large insertion/deletion copy number variants in the LDLR gene. The FH diagnostic algorithm is shown in Figure 1 . We do not recommend nor mandate DNA analysis systematically for all patients.
FH criteria: minor
There are 2 minor criteria: (1) a family history of elevated LDL-C > 95th percentile, according to the LDL-C criteria outlined in the Screening Criteria for FH section in a first-degree relative, according to age; and (2) a history of ASCVD in the proband or in a first-degree relative younger than 55 years for men or younger than 65 years for women. A diagnosis of "definite FH" is on the basis of the LDL-C criterion and 1 major criterion. "Probable FH" is on the basis of the LDL-C criterion and 1 minor criterion. "Severe hypercholesterolemia" refers to the LDL-C criterion (> 95th percentile), but without major or minor criteria for FH.
Sensitivity/specificity analyses
Agreement analyses were carried out using data from 2 large clinical databases in Canada and Australia, comparing the performance of the Canadian definition with that of SBR and the DLCN. Table 1 shows the sensitivity and specificity values for each set of data, the positive and negative predictive values, as well as the Cohen k coefficient. Using the SBR criteria for comparison, the Canadian definition achieved 99.7% sensitivity and 98.9% specificity in the largest data set from Chicoutimi, Quebec, composed of 5987 subjects. 
Discussion
This new definition of FH showed excellent agreement with the most widely used FH criteria, the SBR and DLCN criteria, and is well adapted to the Canadian population. The risk of developing ASCVD in mutation carriers with high LDL-C has been shown to be markedly elevated; identification and early treatment of subjects with FH has been shown to normalize life expectancy. Compared with normolipidemic individuals, ASCVD risk is increased 6-fold when LDL-C is > 5 mmol/L vs noncarriers having LDL-C levels < 3.4 mmol/L and up to 22-fold when a pathogenic DNA FHcausing mutation is present. 4 This is likely related to higher cumulative lifetime vascular exposure to atherogenic lowdensity lipoprotein particles. In this article, we propose a novel definition of FH and online or downloadable applications that should facilitate diagnosis (www.circl.ubc.ca).
We acknowledge limitations to this scheme but this simplified definition will provide physicians and health care professionals a reliable way to diagnose FH and to initiate treatment and cascade screening in affected patients so that appropriate treatment is initiated early and might prevent cardiovascular events and deaths. There is no "gold standard" for a definition of FH and therefore, comparison with existing diagnostic criteria are necessarily limited. We recognize that our LDL-C cut points are arbitrary and that the imputed LDL-C represents the average response to lipid-lowering agents. However, the new LDL-C cut points will minimize the underdiagnosis of FH in young adults as is the case in other criteria such as the SBR criteria.
Some subjects with a causal mutation in the LDLR, APOB, or PCSK9 genes might have an LDL-C < 95th percentile. Nevertheless, a subject with a causal mutation in the LDLR, APOB, or PCSK9 genes remains at elevated ASCVD risk and preventive therapies must be considered. DNA testing for FH is not widely available in Canada, might not detect all types of variants, and is costly. Although a DNA diagnosis is not mandated for a diagnosis of FH, it should be considered in "probable FH" or "severe hypercholesterolemia" cases, when this might influence therapeutic decisions, especially in younger subjects. Approximately 20% of FH patients have a polygenic form of the disease. These patients would not meet the DNA criterion, but might meet the LDL-C and ASCVD criteria, and still require aggressive treatment including a possible need for PCSK9 inhibitors.
Treatment decisions should be at the discretion of the physician and the patient and should follow the 2014 Canadian Cardiovascular Society position statement on FH, 5 and the 2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia (www.onlinecjc.ca/article/S0828-282X(16)30732-2/pdf). The proposed definition for FH will also be particularly useful as a guide to select patients suitable for genetic testing, which is becoming more widely available. Because of the worldwide prevalence of FH, this new definition might be useful in countries other than Canada. The absence of positive genetic testing does not imply lack of risk in patients with LDL-C > 95th percentile, and these individuals still require active treatment to reduce their risk. The opportunity for clinicians to initiate cascade screening from an index patient is a very cost-effective method to identify new patients and initiate treatment and might prove more effective than broad cholesterol screening in childhood.
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This study was funded through FH Canada (www. (ASCVD) and an elevated LDL-C >95 th percentile in a first-degree relative to generate a score that leads to classification of either "definite" or "probable" or "possible" FH, with several other less commonly used criteria. 6, 7 Detection of a pathogenic DNA mutation in a FH-related gene in a proband leads to a diagnosis of "definite FH". Head-to-head comparisons suggest that the Simon Broome Register and DLCN criteria perform similarly well in diagnosing FH patients. 8 There are important limitations to the currently used algorithms: the clinical manifestations of FH, such as premature corneal arcus, xanthelasmas and tendon xanthomas are infrequently present; the baseline LDL-C (untreated) level is often unavailable due to use of lipid lowering therapies; and, family history is sometimes unavailable or unreliable. In addition, DNA testing is not readily available and not always concordant with the FH phenotype. 9 Despite the complexities, diagnosis is important because untreated FH leads to premature ASCVD (before the fourth and fifth decade in men and women, respectively), 2 while early identification and treatment can normalize risk. 10 Heterozygous FH (HeFH) has a prevalence of approximately 1:250 based on a recent metaanalysis 11 and may be higher in populations with founder effects, as observed in the province of Québec. 12 The homozygous form (HoFH) is rare and constitutes an orphan disease. Age of onset of ASCVD can vary considerably in FH subjects and in addition to sex, depends on the severity of the mutation, other concomitant cardiovascular risk factors, and gene-gene and geneenvironment interactions. 13, 14 This increase in ASCVD risk remains across a broad range of elevated LDL-C levels and is at least 6-fold higher even in the absence of documented FH-causing mutations. 15 Currently used criteria are difficult to use in the clinic and, as a consequence, many patients at very high risk of developing ASCVD may be missed. We therefore propose to redefine FH on the basis of simplified criteria as a genetic condition characterized by marked elevations in LDL-C and risk of early onset ASCVD. We provide Canada-specific LDL-C cut-points and a validated calculation for an imputed LDL-C, based on the type and intensity of lipid-lowering therapy. 16 We acknowledge limitations to this scheme but this simplified definition will provide physicians and health care professionals a reliable way to diagnose FH and to initiate treatment and cascade screening in affected patients so that appropriate treatment is initiated early may prevent cardiovascular events and deaths. with a baseline LDL-C>8.5 mmol/L or with tendinous xanthomas with an elevated LDL-C has a mutation of the LDLR or APOB genes. Thus, these constitute criteria for "definite" FH. In accordance with the DLCN and Simon Broome Register criteria, a family history of elevated LDL-C in a first-degree relative or a family history of premature ASCVD in a first-degree relative constitute minor criteria for a diagnosis of "probable". These set of criteria correspond to the "probable" FH category from the Simon Broome Register and both the "possible" and "probable" Canadian FH algorithm. We based a diagnosis of "definite" FH on the presence of the LDL-C screening criteria and one or more of the following major criteria (Supplemental Table S3 ): 1) the presence of extensor tendon xanthomas; 2) the identification of a mutation in the LDLR, APOB or PCSK9 genes known to cause FH in the proband or a first-degree relative; or, 3) an LDL-C level ≥8.5 mmol/L. 5 A "probable" FH diagnosis relies on the presence of one or both of the minor criteria: 1) the presence of an LDL-C ≥95 th percentile (as described above) in a first-degree relative; or, 2) the presence of premature ASCVD, as defined in the 2016 update of the Canadian Cardiovascular Society guidelines for the management of dyslipidemia in the adult 21 in the proband or in a first-degree relative (<55 and <65 years in men and women, respectively). Patients who only have the LDL-C criterion have a "severe hypercholesterolemia" diagnosis, and remain at a risk of ASCVD 6-fold that of age and gender-matched subjects with LDL-C levels <3.4 mmol/L.
15,22
Statistical analysis and validation. The validation of the conversion factors used to impute baseline LDL-C has been previously published. 16 Descriptive statistics and statistical analysis were performed using Stata, version 13.1 (Texas, USA). Patients with a "possible" or "probable" diagnosis were designated as negative cases for the purpose of calculating sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). The Cohen's kappa (κ) coefficient was applied to evaluate the agreement between the new Canadian FH definition and both the Simon Broome Register or DLCN criteria (Supplemental Tables S1 & S2) using data from the Lipidology Unit at the Community Genomic Medicine Centre in Chicoutimi, Québec, Canada (n=5,987), the largest database currently available on FH in Canada. Data from the FH Western Australia program (n=947) were also used to provide an international comparator.
23-25
The extent of agreement among the κ values was interpreted according to the terminology by 
Results
Screening criteria for FH:
Baseline LDL-C. When baseline LDL-C was unavailable, an imputed value for FH diagnosis was used, based on the average response to statins and ezetimibe. 16 The use of a downloadable application (www.FHCanada.net; www.circl.ubc.ca/) facilitates the imputation of LDL-C. The correlation between baseline LDL-C and imputed LDL-C has been previously published (r=0.76,
p<0.001).
16 LDL-C cut-points. The 95 th percentile cut-points for LDL-C were determined in 3,366,046 subjects from the province of Ontario 19 and are shown in Figure 1 ; frequency distribution according to age and sex is shown in Supplemental Table S4 . Overall, the 95 th percentile for the population was 5.0 mmol/L in men and in women. The 95 th percentile value for LDL-C in men <18, 18-39 and >40 years were 3.67, 4.79 and 5.08 mmol/L, respectively. In women, these were 3.70, 4.27 and 5.18 mmol/L, respectively. We therefore selected the LDL-C cut-points of ≥4.0 mmol/L for men and women <18 years, ≥4.5 mmol/L for ages 18-39 and ≥5.0 mmol/L for subjects ≥40 years of age. These LDL-C levels constitute an obligatory major criterion for the diagnosis of FH and should be confirmed on repeat testing.
Along with the DLCN criteria, examination of existing Canadian databases confirms that LDL-C levels ≥8.5 mmol/L has >99% specificity for a diagnosis of FH in genetically confirmed patients (data not shown). However, the sensitivity of this criterion is weak. In many cases, the baseline (untreated) LDL-C level is either based on historical values or is unknown because the patient was started on lipid-lowering therapy and often high intensity statin after an acute coronary syndrome. Figure   S1 ). However, tendon xanthomas, which are highly specific of FH in subjects with genetic high LDL-C, are included in both the DLCN and Simon Broome Register criteria as a major clinical diagnostic criterion 27 (Supplemental Tables S1 & S2 
FH criteria: Minor
There are two minor criteria: 1) a family history of elevated LDL-C >95 th percentile, according to the criteria outlined below in a first-degree relative, according to age; and 2) a history of ASCVD in the proband or in a first-degree relative <55 for men or <65 years for women. A diagnosis of "definite FH" is based on the LDL-C criterion and one major criterion. "Probable FH"
is based on the LDL-C criterion and one minor criterion. "Severe hypercholesterolemia" refers to the LDL-C criterion (>95 th percentile), but without major or minor criteria for FH.
Sensitivity/Specificity analyses.
Agreement analyses were carried out using data from two large clinical databases in Canada and Australia, comparing the performance of the Canadian definition with that of Simon Broome Register and the DLCN. Table 1 
Discussion
To facilitate the diagnosis of FH and the identification of patients who are likely to benefit from preventive therapy, we have first established LDL-C cut-points for a large population in Canada and determined major and minor criteria for FH in the Canadian context. We propose a simplified Canadian definition for FH that relies on 1) LDL-C levels; 2) major criteria of the presence of xanthomas, LDL-C ≥8.5 mmol/L or DNA mutation causing FH in proband or a firstdegree relative; and 3) minor criteria of premature ASCVD (<55 years in men, <65 years in women) in proband or a first-degree relative or elevated LDL-C in a first-degree relative. This new Canadian definition of FH showed excellent agreement with the most widely used FH criteria, the Simon Broome Register and DLCN criteria, and is well-adapted to the Canadian population.
The diagnosis of FH has evolved over the past decades, owing to clarification of the genetic basis, the changing phenotype and awareness of the clinical implications. Once considered a relatively uncommon disorder with a prevalence of 1:500, a more recent meta-analysis of published studies shows a prevalence of ~1:250, making FH the most common monogenic disorder encountered in clinical practice. 11 The risk of developing ASCVD in mutation carriers with high LDL-C has been shown to be markedly elevated; 15, 35 identification and early treatment of subjects with FH has been shown to normalize life expectancy. 2 Compared to normolipidemic individuals, ASCVD risk is increased 6-fold when LDL-C is >5 mmol/L versus non-carriers having LDL-C levels <3.4 mmol/L and up to 22-fold when a pathogenic DNA FH-causing mutation is present. 15, 22, 35 This is likely related to higher cumulative lifetime vascular exposure to atherogenic LDL particles. Yet, the diagnosis of FH remains the province of specialized physicians, especially lipidologists. Here, we propose a novel definition of FH and on-line or downloadable applications that should facilitate diagnosis. 36, 37 This new simplified definition has a remarkably high degree of agreement with the Simon Broome Register and DLCN criteria.
We acknowledge limitations to the present study. There is no "gold standard" for a definition of FH and therefore, comparison to existing diagnostic criteria are necessarily limited. We recognize that our LDL-C cut-points are arbitrary and that the imputed LDL-C represents the average response to lipid-lowering agents and are based on branded and not generic agents.
However, the new LDL-C cut-points will minimize the under-diagnosis of FH in young adults as is the case in other criteria such as the Simon Broome Register criteria. For children, we kept the LDL-C cut-point of >4.0 mmol/L although an LDL-C >3.5 mmol/L is strongly predictive of FH in this age-group, 38 for which the issue of definite diagnosis is important since it infers an LDL risk that is present starting at birth and extending across the lifespan. Early treatment has been shown to be more effective than later treatment, and a lifetime of low risk is necessary to achieve normal vascular health across the lifespan. Detection, diagnosis and treatment of FH early in life is, therefore, essential.
Some subjects with a causal mutation in the LDLR, APOB or PCSK9 genes may have an LDL-C <95 th percentile. 8 Nevertheless, a subject with a causal mutation in the LDLR, APOB or PCSK9 genes remains at elevated ASCVD risk and preventive therapies must be considered. 15 These patients would not meet the DNA criterion, but may meet the LDL-C and ASCVD criteria, and still require aggressive treatment including possible need for PCSK9 inhibitors.
This simplified definition of FH should enable physicians to recognize and treat a frequent monogenic lipoprotein disorder that carries a very high risk of ASCVD in affected subjects. 41 The proposed definition for FH will also be particularly useful as a guide to select patients suitable for genetic testing, which is becoming more widely available in the country. Given the worldwide prevalence of FH, this new definition might be useful in countries other than Canada. The absence of positive genetic testing does not imply lack of risk in patients with LDL-C >95 th percentile, and these individuals still require active treatment to reduce their risk. Worldwide, FH is underdiagnosed and considerable efforts are being implemented to raise awareness internationally. [42] [43] [44] The opportunity for clinicians to initiate cascade screening from an index-patient is a very cost-effective method to identify new patients and initiate treatment [45] [46] [47] [48] and may prove more effective than broad cholesterol screening in childhood. 49 The role of registries for FH stems from the European experience (especially the Netherlands and Norway) 2, 50 and such a registry is being implemented in Canada (www.FHCanada.net). The experience of the British Columbia FH Registry shows the importance of learning from such a registry.
51
Conclusions
To provide physicians and health care professionals a reliable way to detect FH and to initiate treatment and cascade screening in affected patients, we propose a pragmatic, simplified definition of FH. The proposed definition is adapted to the Canadian population, and shows diagnostic performance comparable to existing criteria. We expect that it will facilitate the identification of FH patients and help prevent cardiovascular events and deaths associated with this condition.
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